Melanoma Clinical Trials

Showing 141-160 of 705 trials

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

NCT05004025

Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune checkpoint inhibitors.

Uveal Melanoma

HonorHealth Research Institute10 participantsStarted Feb 2022

Scottsdale, Arizona, United States • Los Angeles, California, United States

ENROLLING_BY_INVITATIONPHASE1

HS-IT101 Injection in the Treatment of Advanced Melanoma

NCT06941818

Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced melanoma.

Advanced Melanoma

Qingdao Sino-Cell Biomedicine Co., Ltd.10 participantsStarted Jul 2025

Beijing, China

COMPLETED

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

NCT04825834

The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.

Lung CancerHead and Neck CancerEsophageal Cancer+7 more

Delfi Diagnostics Inc.2,992 participantsStarted Mar 2021

Homewood, Alabama, United States • Peoria, Arizona, United States • Fayetteville, Arkansas, United States +54 more locations

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

HS-IT101 Injection in the Treatment of Advanced Melanoma

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Related Searches

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

A Model for Genetic Susceptibility: Melanoma

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

eFLASH for Skin Lesions of Malignant Melanomas

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Implementation of Teledermoscopy and Artificial Intelligence

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Evaluation of Skin Tests in Biotherapy Allergies

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders